Tumor-associated glycosaminoglycans (GAGs) are emerging as critical biomarkers and therapeutic targets in oncology. Unlike normal extracellular matrix components, GAGs in the tumor microenvironment often exhibit distinct sulfation patterns, chain lengths, and protein modifications.
